Erythropoiesis-stimulating agents (ESAs)
Title
Date Published
Erythropoietin as a treatment of anemia in heart failure: Systematic review of randomized trials.
May 1, 2011
C.E.R.A. once every 4 weeks corrects anaemia and maintains haemoglobin in patients with chronic kidney disease not on dialysis.
April 19, 2011
An update on the controversies in anemia management in chronic kidney disease: lessons learned and lost.
April 10, 2011
Darbepoetin alfa for anemia in patients with low or intermediate-1 risk myelodysplastic syndromes and positive predictive factors of response.
March 7, 2011
An observational study of the effectiveness of darbepoetin alpha administered in dialysis patients once every 2 weeks for 12 months.
March 1, 2011
Preoperative methods to improve erythropoiesis.
January 31, 2011
Usage of erythropoiesis-stimulating agents in cancer patients at an academic cancer center and experience with specific care management tools for anemia.
January 24, 2011
Twist and shout: one decade of meta-analyses of erythropoiesis-stimulating agents in cancer patients.
December 8, 2010
A prospective, observational study describing the haematological response in patients undergoing chemotherapy treated by tri-weekly darbepoetin alfa for anaemia.
October 11, 2010
Conversion of darbepoetin to low doses of CERA maintains hemoglobin levels in non-dialysis chronic kidney disease patients.
October 6, 2010
Erythropoietin treatment in patients with combined heart and renal failure: objectives and design of the EPOCARES study.
July 31, 2010
Antiepoetin antibody-related pure red cell aplasia: successful remission with cessation of recombinant erythropoietin alone.
July 23, 2010
Thrombotic complications of erythropoiesis-stimulating agents.
July 14, 2010
Comparative efficiency and hemorheological consequences of hemotransfusion and epoetin therapy in anemic cancer patients.
June 30, 2010
Target haemoglobin to aim for with erythropoiesis-stimulating agents: a position statement by ERBP following publication of the Trial to Reduce Cardiovascular Events with Aranesp(R) Therapy (TREAT) Study.
June 29, 2010
Erythropoietin preserves the integrity and quality of organs for transplantation after cardiac death.
June 22, 2010
Impact of erythropoiesis-stimulating agents on morbidity and mortality in patients with heart failure: an updated, post-TREAT meta-analysis.
June 5, 2010
Darbepoetin alfa 300 or 500 mug once every 3 weeks with or without intravenous Iron in patients with chemotherapy-induced anemia.
June 4, 2010
The preoperative use of erythropoietin stimulating proteins prior to radical prostatectomy is not associated with increased cardiovascular or thromboembolic morbidity or mortality.
June 1, 2010
Anemia correction by erythropoietin reduces BNP levels, hospitalization rate, and NYHA class in patients with cardio-renal anemia syndrome.
May 29, 2010